Skip to main content
Fig. 8 | Stem Cell Research & Therapy

Fig. 8

From: IL-1β-primed mesenchymal stromal cells exert enhanced therapeutic effects to alleviate Chronic Prostatitis/Chronic Pelvic Pain Syndrome through systemic immunity

Fig. 8

Schematic of IL-1β-primed MSCs in the modulation of macrophages, monocytes, Treg cells, systemic inflammatory response, prostate inflammation, and pelvic pain in CP/CPPS mice. In systemic immunity, IL-1β-primed MSCs regulated the inflammatory properties of macrophages from M1 to M2, CD11b+Ly6Chigh monocyte less infiltration and Treg cell accumulation. The above immune cells enhanced inflammatory resolution, inhibited NF-κB, STAT3 and JNK activation of inflammatory sites and inhibited the release of CCL2 in the prostate via systemic immunity

Back to article page